ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B Without Inhibitory Antibodies to Factor VIII or IX

Enrolling By Invitation
99 years or below
All
Phase 3
1 participants needed

Brief description of study

This study will evaluate the efficacy and safety of fitusiran compared to on-demand treatment with factor concentrates, as determined by the frequency of bleeding episodes in enrolled patients.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hemophilia
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 828210
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

 

Interested in the study?

Message For Enrolling By Invitation Trial

study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact a study center.